XML 63 R47.htm IDEA: XBRL DOCUMENT v3.26.1
Other Intangible Assets (Details) - USD ($)
 12 Months Ended
Apr. 29, 2024
Apr. 26, 2024
Aug. 15, 2023
Dec. 31, 2024
Jun. 06, 2025
Other Intangible Assets          
Accrual for intangible asset milestone obligation       $ 2,000,000  
Issuance of common stock as consideration for licensing agreement [1]       436,809  
Change in fair value of equity consideration payable       (1,240,800)  
Impairment of intangible assets       6,100,000  
License | Formosa Pharmaceuticals Inc          
Other Intangible Assets          
Percentage of product approved by FDA     0.05%    
Upfront payment     $ 2,000,000    
Accrual for intangible asset milestone obligation   $ 2,000,000   2,000,000  
Upfront payment paid in cash   $ 1,000,000 $ 1,000,000    
Issuance of common stock as consideration for licensing agreement (in shares) 7,668   6,097    
Legal expenses capitalized     $ 122,945    
Maximum amount payable upon achievement of certain development milestones     4,000,000    
Maximum amount payable upon achievement of certain sales milestones     80,000,000    
Initial development milestone payment which trigger FDA approval     $ 2,000,000 2,000,000  
Issuance of common stock as consideration for licensing agreement $ 400,000        
Change in fair value of equity consideration payable       600,000  
Impairment of intangible assets       $ 6,100,000  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]       Other Asset Impairment Loss  
Total obligations         $ 2,200,000
[1] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.